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Abstract
Background: The human polyomavirus, JC virus (JCV) produces five tumor proteins encoded by transcripts alternatively
spliced from one precursor messenger RNA. Significant attention has been given to replication and transforming activities
of JCV’s large tumor antigen (TAg) and three T9 proteins, but little is known about small tumor antigen (tAg) functions.
Amino-terminal sequences of tAg overlap with those of the other tumor proteins, but the carboxy half of tAg is unique.
These latter sequences are the least conserved among the early coding regions of primate polyomaviruses.
Methodology and Findings: We investigated the ability of wild type and mutant forms of JCV tAg to interact with cellular
proteins involved in regulating cell proliferation and survival. The JCV P99A tAg is mutated at a conserved proline, which in
the SV40 tAg is required for efficient interaction with protein phosphatase 2A (PP2A), and the C157A mutant tAg is altered
at one of two newly recognized LxCxE motifs. Relative to wild type and C157A tAgs, P99A tAg interacts inefficiently with
PP2A in vivo. Unlike SV40 tAg, JCV tAg binds to the Rb family of tumor suppressor proteins. Viral DNAs expressing mutant t
proteins replicated less efficiently than did the intact JCV genome. A JCV construct incapable of expressing tAg was
replication-incompetent, a defect not complemented in trans using a tAg-expressing vector.
Conclusions: JCV tAg possesses unique properties among the polyomavirus small t proteins. It contributes significantly to
viral DNA replication in vivo; a tAg null mutant failed to display detectable DNA replication activity, and a tAg substitution
mutant, reduced in PP2A binding, was replication-defective. Our observation that JCV tAg binds Rb proteins, indicates all
five JCV tumor proteins have the potential to influence cell cycle progression in infected and transformed cells. It remains
unclear how these proteins coordinate their unique and overlapping functions.
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Introduction
JC virus (JCV) belongs to the Polyomaviridae family of small
double-stranded DNA tumor viruses that includes four other
human polyomaviruses: BKV, WUV, KIV and MCV. These five
viruses are distributed globally among the human population with
seroprevalence ranging from 39% to 82% among healthy adult
blood donors [1]. Some studies have suggested that simian virus 40
(SV40), the prototype member of the primate polyomavirus
subgroup, also circulates in humans as a consequence of exposure
to virus present in early preparations of poliovirus vaccine. The
JCV, BKV and SV40 genomes share a high degree of sequence
homology (69–75%) and organization of the viral genes is nearly
identical [2], but the viruses do exhibit distinct biological
differences. For example, JCV exhibits restricted growth and
oncogenic potential in cell culture, in part due to highly tissue-
specific transcriptional signals and early regulatory proteins that
appear to be less robust than those of SV40 [reviewed in 3–6]. A
comparison of the primate polyomavirus genomes indicates that
promoter-enhancer sequences have diverged to the greatest extent.
JCV produces five early proteins, the large tumor antigen (TAg),
small tumor antigen (tAg), and three T9 proteins, which share
overlapping N-terminal sequences and exhibit common and
unique replication and transforming functions [7,8]. The SV40
genome encodes three early proteins, TAg, tAg, and 17KT that,
like the JCV early regulatory proteins, are encoded by alterna-
tively spliced early transcripts.
TAg is the major polyomavirus tumor protein. At least three
distinct TAg domains contribute to oncogenic transformation. The
J domain, named for functional and sequence similarities to
cellular DnaJ co-chaperones, binds to the molecular chaperone
Hsc70. This domain, in cooperation with a second motif, the
LxCxE domain, regulates cell cycle progression, in part, by
interacting with the Rb family of proteins, activating the intrinsic
ATPase activity of Hsc70 and effecting the release of members of
the E2F family of transcription factors from their Rb partners
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substrate 1 (IRS1) through its LxCxE domain, leading to
activation of PI3 kinase (PI3K), which in turn up-regulates
phosphorylation of Akt [10]. The third transformation domain of
TAg is a C-terminal bipartite region that directly binds and
inactivates the tumor suppressor protein p53 [11]. Binding of
SV40 TAg to p53 promotes the recruitment of CBP/p300, which
in turn influences TAg acetylation [12,13] and stability, and
impacts oncogenic transformation of NIH-3T3 cells [14]. JCV
TAg has also been reported to interact with b-catenin,
contributing to cellular transformation. b-catenin, a key member
of the Wnt pathway, is stabilized and imported to the nucleus
through a physical interaction with JCV TAg where it up-regulates
expression of proteins involved in cell growth and proliferation
[15].
Although the oncogenic mechanisms of the primate polyoma-
virus TAgs have received much attention, the essential activities of
this multifunctional protein relate to its role in mediating viral
DNA replication. Many of the TAg sequences required for
initiation and elongation of replication reside in the unique C-
terminal region of the protein [5]. However, N-terminal sequences
shared with the other tumor proteins, including tAg and the TAg
splice variants (17KT, T9 proteins), also influence viral DNA
replication. For example, the J domain of TAg is required for
efficient viral DNA replication [16], yet few data are available that
address the replication functions of these same sequences in the
other tumor proteins.
JCV tAg has only recently become a focus of study; however, a
number of functions of the related SV40 tAg are known. SV40 tAg
cooperates with TAg to enhance transformation when TAg levels
are low or quiescent cells are being tested [reviewed in 17,18].
SV40 tAg expression is dispensable for TAg-mediated transfor-
mation of dividing rodent cells, but is required for transformation
of human cells [19]. In addition, tAg stimulates, but is not essential
to, viral replication in permissive cells [20]. This stimulation likely
results from the ability of tAg to alter the activity of cellular protein
phosphatase 2A (PP2A), which in turn may lead to changes in the
phosphorylation state of critical serine and threonine residues
regulating TAg replication functions [reviewed in 20,21]. SV40
tAg is also critical to the maintenance of high viral DNA copy
numbers in persistent infections of human mesothelial cells; in the
absence of tAg, cells are immortalized but not transformed, and
only low copy numbers are maintained [22].
Unique sequences within the SV40 and murine polyomavirus
tAgs are responsible for the binding of PP2A [23–25], a
phosphatase that regulates numerous cell activities by dephos-
phorylating a variety of substrates. Making up as much as 1% of
total cell protein [26], PP2A is a modular holoenzyme consisting
of three subunits. A large number of regulatory subunit B
isoforms directs functional specificity when joined to the core
enzyme composed of the scaffolding subunit A and the catalytic
subunit C [25,26]. For example, pools of holoenzymes with
specific B subunits are formed differentially during the course of
the cell cycle, and the PP2A holoenzymes with cell-cycle-specific
regulatory subunits orchestrate cell cycle progression [27].
Various viral proteins form complexes with the AC core [21],
and some partially displace B subunits already complexed in the
holoenzyme [24]. Through co-immunoprecipitation (co-IP)
experiments, SV40 tAg was associated with the A and C subunits
of PP2A [28,29]. Addition of SV40 tAg to the AC core alters the
subcellular localization of PP2A [30] as well as the phosphatase
activity of the holoenzyme, and modulates protein kinase
signaling pathways [21,31], thus potentially influencing the cell
cycle.
SV40 tAg facilitates the transformation of cells by activating
phosphorylation of PI3K in a PP2A-dependent fashion, which in
turn up regulates the activity of multiple signal transduction
pathways [reviewed in 32]. The cellular kinase Akt, part of the
PI3K-Akt pathway, contributes to enhanced activity of telomerase,
a necessary but not sufficient step in the oncogenic progression of
human cells [33]. Akt has two phosphorylation sites: T308, in the
activation loop of the kinase, and S473, at the carboxyl terminus.
Depending on cell growth conditions, phosphorylation of T308
alone or T308 and S473 together may be stimulated through the
PI3K pathway following binding of PP2A by tAg [34]. TAg has
also been shown to effect modification of both residues in Akt
through its binding to IRS1 [10].
Here, we have examined the interaction of wild-type and
mutant JCV tAgs with PP2A and members of the Rb family in
cultured cells, and have investigated tAg functions that may
influence JCV transforming and DNA replication potential.
Materials and Methods
Generation of Viral DNA Constructs
We have adopted a uniform naming scheme for the recombi-
nant DNAs (rDNAs) constructed for this study. For clarity,
plasmids previously described have been renamed according to
this scheme, with the original name indicated in parentheses after
the first mention of each construct in the text. Expression of TAg
(T), tAg (t), or the three T’ proteins (T9135,T 9136,T 9165)i s
indicated by a plus (+); lack of expression is denoted by a minus (-)
sign. An amino acid substitution, for example the alteration of
proline at residue 99 of tAg to alanine, is indicated by the single
letter abbreviation of the wild type (P) and altered (A) amino acid
with the residue number (99) identified between these letters. The
viral source of the transcription signals effecting gene expression is
noted at the start of each name. JR, SR and CMV denote the
JCV, SV40 and cytomegalovirus regulatory regions, respectively.
Therefore, the rDNA, SR:T
+/P99At
+/T9
+, expresses the JCV
wild type TAg and T9 proteins and the mutant P99A tAg under
the control of the SV40 promoter/enhancer signals.
pCMV:T
+/t
+/T9
+ (previously pCMV-JCVE; [8]) expresses all
five JCV early proteins via the CMV early promoter in the pCR3
vector (Invitrogen). pCMV:T
+/t
2/T9
2 (previously pCMV-DT9;
[8]) expresses TAg only. pCMV:T
+/t
2/T9
+ (previously pCMV-
JCT; [8]) expresses TAg and the three T9 proteins, but not tAg.
pJR:T
+/t
2/T9
+ was constructed by first digesting pCMV:T
+/
t
2/T’
+ with NcoI and PstI to isolate the DNA fragment containing
TAg cDNA coding sequences. This fragment was ligated to
pJR:T
+/t
+/T9
+ (previously pMRMMT; [35]) which had been
digested with the same restriction enzymes to remove the
corresponding sequence. To create a second construct expressing
these same JCV proteins but under the control of SV40
transcription signals (pSR:T
+/t
2/T’
+), the JCV regulatory region
was removed from pJR:T
+/t
2/T9
+ by NcoI cleavage and replaced
with the SV40 regulatory sequences obtained by NcoI digestion of
pSR:T
+/t
+/T’
+ (previously pSRMMT; [35]). The expected
structures of the pJR:T
+/t
2/T9
+ and pSR:T
+/t
2/T’
+ rDNAs
were confirmed by DNA sequence analysis.
PCR was performed to generate a JCV tAg expression plasmid.
An mRNA template from PHFG cells transfected with JCV DNA
was amplified with primers tAg cDNA R (59-GAG CTT ATG
GAT TTA TTA GGC CTT GAT AGG TCT GCA TGG-39), nt
4980–4942, and tAg cDNA F (59-GCT ATC CAT AGG TTG
GCA CCT TAA AGC TTT AGA TCC CTG TAG G-39), nt
4412–4426, 4494–4517 with 4 non-JCV nt at the 59 end. The
product, a DNA fragment containing the tAg cDNA, was ligated
JCV Small t Protein Functions
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sequenced. The tAg cDNA contained one mutation, an artifact
of the PCR amplification step, at nucleotide (nt) 4605. The
resulting plasmid was digested with EcoNI and PflMI to isolate the
tAg cDNA, which was ligated to pCMV:T
+/t
2/T9
+ from which
the corresponding sequence had been removed. The resulting
mutant tAg expression vector, pCMV:T
2/mut
+/T’
2, was sub-
jected to PCR-mediated site-directed mutagenesis to correct the
point mutation using primers WTtAgL (59-GCA ATC AAA GCA
ATA GCA ATC TAT CCA CAC AAG TGG GC -39), and
WTtAgE (59-GCC CAC TTG TGT GGA TAG ATT GCT ATT
GCT TTG ATT GC-39), which span the coding sequence from nt
4628–4591. The tAg coding region of the PCR product was
confirmed by DNA sequence analysis. The sequenced region,
which contained the wild type tAg cDNA sequence, was isolated
and ligated to the pCMV:T
2/mut
+/T’
2 backbone with the
corresponding region removed. This step ensured that any
secondary mutations inadvertently introduced via PCR would
not be present in the final construct. Next, the tAg cDNA region
was isolated following BstXI and PstI digestion and ligated to
pJR:T
+/t
+/T9
+ with the corresponding sequence removed, to
create pJR:T
2/t
+/T’
2. The expected structure of the rDNA was
confirmed by DNA sequence analysis.
pJR:T
+/t
+/T9
+ and pSR:T
+/t
+/T9
+ contain wild-type JCV
coding sequences linked to either the JCV or SV40 regulatory
region, respectively. Each plasmid was used as a template for site-
directed mutagenesis to generate constructs encoding P99A or
C157A mutant tAgs. Complementary primers P99AR (59-CC
CTT TAT TGC AAG GAA TGG GCT AAC TGT GCC ACT
AAT CC-39) and P99AF( 59-GG ATT AGT GGC ACA GTT
AGC CCA TTC CTT GCA ATA AAG GG-39), which span the
coding sequence from nt 4739–4700, or C157AF (59-CCC AAG
AAG CTC TTC ATT CCT GGG AGA AAG TTC TTG G-39)
and C157AR (59-CCA AGA ACT TTC TCC CAG GAA TGA
AGA GCT TCT TGG G -39), which span the coding sequence
from nt 4562–4526, were used. Altered nucleotides are in bold and
underlined. The PCR products were sequenced, and the regions of
interest were removed by BstXI and PflMI digestion. The
fragments containing the point mutations were ligated to
pJR:T
+/t
+/T9
+ or pSR:T
+/t
+/T9
+ backbone vectors to create
pJR:T
+/P99At
+/T9
+, pJR:T
+/C157At
+/T9
+, pSR:T
+/P99At
+/
T9
+ and pSR:T
+/C157At
+/T9
+. The structure of each construct
was confirmed by DNA sequence analysis.
To generate pJR:T
2/H42Qt
+/T9
2, PCR-mediated site-specific
mutagenesis was performed on pSR:T
+/t
+/T9
+ using primers
H42Qf (59-CCCCACCTTTATCAGGTTGGAGTTCTTTGC-
39) and H42Qr (59-GCAAAGAACTCCAACCTGATAAAGGT-
GGGG-39), which span the coding sequence from nt 4901–4872.
The region spanning the H42Q mutation in the cloned PCR
amplicon was subjected to DNA sequence analysis, isolated by
restriction enzyme digestion, and ligated to the pJR:T
2/t
+/T9
2
backbone from which the corresponding fragment was removed
via digestion. The rDNA structure was confirmed by DNA
sequence analysis.
Cell Culture
Primary human fetal glial (PHFG), Rat2, mouse embryo
fibroblast (MEF) and 3T3 (3T3-Swiss albino; American Type
Culture Collection) cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% (PHFG) or 5%
(R2, MEF, 3T3 cells) fetal bovine serum (FBS), 100 U/ml
penicillin and 0.1 mg/ml streptomycin. U-87MG cells were
cultured in minimum essential Eagle’s medium (MEM) with
10% FBS, 2% sodium pyruvate, 100 U/ml penicillin and 0.1 mg/
ml streptomycin. All cells were incubated at 37uC in 10% CO2.
Generation of Cell Lines
To create cell lines stably expressing all 5 JCV early proteins
(T
+/t
+/T9
+,T
+/P99At
+/T9
+,T
+/C157At
+/T9
+), or small tAg
alone (T
2/t
+/T9
2), 3T3 cells in 100 mm dishes were co-
transfected with 5 mg of DNA encoding JCV proteins driven by
SV40 promoter-enhancer signals, and 0.5 mg of pCR3, which
confers G418 [geneticin] resistance. Cells were selected for G418
resistance in the presence of 400 mg/ml geneticin in complete
growth medium. Isolated colonies arising from single cells were
transferred to new plates at 14 to 21 days post-transfection (p.t.).
Protein extracts prepared from these cells were subjected to
immunoprecipitation (IP) and Western blot (WB) analyses to
confirm viral protein expression.
Immunoprecipitation and Western Blot (IP/WB) Analysis
Cell extracts were prepared with EBC lysis buffer (50 mM Tris,
pH 8.0, 120 mM NaCl, 0.5% NP-40) supplemented with protease
and phosphatase inhibitors (2 mg/ml leupeptin, 2 mg/ml E-64,
1 mg/ml aprotinin, 0.25 mM pefabloc, 1 mM sodium vanadate,
5 mM sodium fluoride, 25 mM b-glycerophosphate and 5 mM
EDTA). Protein concentrations were determined by the Bradford
assay using a micro protein assay (Bio-Rad Laboratories).
Following initial IP experiments, the amounts of total protein in
different cell lysates were adjusted to yield equivalent levels of tAg.
These protein extracts were incubated with either the anti-JCV
TAg monoclonal antibody PAb 962 [36] or anti-p107 antibody
(C-18; Santa Cruz Biotechnology, Inc.) for one hour or with anti-
PP2A-C antibody (clone ID6; Upstate Biotechnology) overnight
on a rotary shaker at 4uC. Protein-antibody complexes were
collected on Staph A (PANSORBIN; Calbiochem). After washing
the pellets 3 times with EBC buffer, the protein complexes were
disrupted by the addition of loading buffer and heating at 95uC for
4 minutes. Proteins were separated on SDS-polyacrylamide gels
and transferred to nitrocellulose membranes. The membranes
were incubated with a cocktail of anti-TAg monoclonal antibodies
(PAb 962, 2000, 2001, 2003, 2024, 2030; [7]) to enhance
detection, or with anti-p107 antibody. After exposing the
membranes to BCIP/NBT (Sigma), secondary antibodies conju-
gated to alkaline phosphatase permitted visualization of the
proteins.
DpnI DNA Replication Assay
JCV DNA-containing vectors were digested with EcoRI to
separate viral and plasmid DNAs. The linear viral DNA was self-
ligated under dilute conditions to produce circular viral DNA.
PHFG cells were seeded onto 60 mm plates and transfected
24 hours later with 100 ng of circular viral DNA using a modified
DEAE-dextran protocol [37,38]. At various time points low
molecular weight DNA was extracted from the cells using the
Hirt protocol [39]. This DNA was cleaved with DpnIa n dEcoRI,
and digestion products were electrophoresed on a 0.8% agarose
gel. DNA was transferred to a nitrocellulose membrane using a
Rapid Downward Transfer System and an alkaline transfer
protocol (Schleicher and Schuell, Amersham). After exposure to
UV light for 5 minutes to cross-link the DNA to the membrane,
the DNA was hybridized with linear JCV DNA labeled with
[a-
32P] dCTP (Prime-a-Gene kit, Promega). Replication activity
was determined by quantitating band intensities of linear DpnI-
resistant viral DNA using ImageQuant 5.2 software (Molecular
Dynamics).
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JCV tAg Interacts with PP2A
The ability of polyomaviruses to induce S phase progression of a
host cell is critical to the establishment of a productive infection.
The early proteins of these viruses target a number of cellular
factors to overcome normal cell cycle control mechanisms. The
cellular phosphatase, PP2A, represents one such target as it
regulates several important cell signal transduction pathways and
is critical to cellular proliferation. Recently, Sariyer and co-
workers [40] demonstrated an in vitro interaction between
bacterially-produced JCV tAg fused to GST and PP2A present
in extracts of U-87MG tumor cells. To demonstrate that this
interaction occurs in vivo, lysates of Rat2, MEF and 3T3 cells
expressing untagged JCV proteins were subjected to co-IP/WB
analysis. A physical interaction between PP2A subunit C and JCV
tAg was detected when anti-PP2A-C antibody was used for the IP
step and WB was performed using anti-T protein antibodies
(Fig. 1); the interaction was also detected when the order of
antibodies was reversed (data not shown). These interactions
between PP2A and tAg were detected in rat and mouse cells
expressing all five JCV early proteins (Fig. 1, lanes 9–11), as well as
in mouse cells expressing tAg only (Fig. 1, lane 12).
Mutant JCV tAgs Interact with PP2A
The unique C-terminal region of SV40 tAg contains a
sequence, including two cysteines and a proline, which contributes
to the tAg-PP2A interaction [23]. Alteration of any of the three
residues reduces PP2A binding; substitution of alanine for the
proline reduces binding to the greatest extent [23]. In addition,
two motifs identified in the unique tAg sequence contain clusters of
three cysteines that are involved in binding zinc ions. Mutation of
any of the six cysteines in these two clusters reduces tAg stability,
resulting in a half-life of 30–-60 minutes [41]; these motifs may
also influence PP2A binding. The three sets of cysteine-containing
sequences in the SV40 protein are conserved in the JCV tAg;
CxxxPxC (amino acids 95–101) and CxCxxC (amino acids 109–
114; Cluster 1 and 136–141; Cluster 2) (Fig. 2). A recent study
performed with JCV tAg deletion mutants found that amino acids
82 to 124 are critical to PP2A binding in vitro [40]. Based on this
information, we substituted an alanine for the conserved proline at
residue 99 in the JCV tAg. This residue is also immediately
Figure 1. Wild type tAg interacts with cellular phosphatase PP2A in cells expressing JCV early proteins. JCV early proteins, expressed in
Rat 2 (R2) or MEF cells transformed with pSR:T
+/t
+/T’
+ or in G418-selected 3T3 cells transfected with pSR:T
+/t
+/T’
+ (encodes all 5 JCV early proteins) or
pSR:T
2/t
+/T’
2 (encodes JCV tAg only) were incubated with anti-T monoclonal antibody PAb 962 (a-T; lanes 4–7) or anti-PP2A antibody (a-PP2A; lanes
9–12). The amount of total cell protein subjected to IP in lanes 9–12 was four times that employed in the corresponding samples in lanes 4–7.
Immunoprecipitated proteins were separated on a 20% SDS-polyacrylamide gel, and WB analysis was performed using a cocktail of anti-T
monoclonal antibodies to detect JCV early proteins either expressed in the different cell lines (lanes 4–7) or expressed and bound to PP2A (lanes 9–
12). Untransfected 3T3 and Rat 2 cells were included as negative controls (no JCV T proteins are present; lanes 1, 2), and a-mouse IgG was used in the
IP step with the R2:T
+/t
+/T’
+ cell extract to test for non-specific binding (lanes 3, 8). The asterisks denote antibody light and heavy chains. This figure
represents proteins electrophoresed on a single gel and transferred to a membrane, which was then cut in half and each half developed for different
lengths of time.
doi:10.1371/journal.pone.0010606.g001
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tAg (Fig. 2). In addition, a cysteine (residue 157) present in a
second LxCxE motif in the JCV tAg (residues 155–159) was
changed to an alanine. Both tAg point mutants were examined for
their ability to bind to PP2A and to members of the Rb family of
tumor suppressor proteins.
3T3 cells were stably transfected with DNA constructs encoding
the wild type, P99A or C157A tAgs. Lysates were prepared from
cells expressing all five JCV early proteins or tAg only, and total
protein amounts used in co-IP experiments were adjusted to yield
comparable tAg levels. These protein extracts were immunopre-
cipitated either with anti-T or anti-PP2A antibody and blotted
with anti-T-protein antibodies (Fig. 3). Relative to PP2A-tAg
interactions observed in two independently-derived cell lines
expressing wild type JCV early proteins (Fig. 3A, lanes 5, 6),
binding of PP2A to the mutant P99A tAg in two different lines was
nearly undetectable (Fig. 3A, lanes 7, 8). The binding of mutant
C157A tAg to PP2A in one cell line was similar to that of the wild
type tAg (Fig. 3B, compare lane 8 with lanes 6, 7), but binding of
the tAg in the second C157A line was reproducibly higher than
that of wild type tAg (Fig. 3B, compare lane 9 with lanes 6, 7).
Binding to PP2A was again observed in cells producing wild-type
tAg in the absence of the other four JCV early proteins (Fig. 3B,
lane 10). As observed in the first set of experiments (Fig. 1), the
tAg-PP2A interaction in this 3T3 cell line was less robust than that
observed in cells expressing all five JCV early proteins.
JCV tAg Physically Interacts with Members of the Rb
Family of Proteins
Bollag and co-workers [7] demonstrated that the LxCxE motif
present in the JCV TAg and T9 proteins binds members of the Rb
family of tumor suppressor proteins. While performing these co-
IP/WB experiments, a 20 kDa band was observed to interact with
p107 and p130. Although JCV tAg is 20 kDa, it was ruled out
because an LxCxE motif had not been identified in any of the
polyomavirus tAgs. Upon reexamination of the JCV sequence, we
recognized two LxCxE domains in the unique C-terminal coding
region of JCV tAg (Fig. 2). The first of these, residues 93–97, is
common to JCV and BKV but not to SV40 or the other 3 human
polyomaviruses (WUV, KIV, MCV); the second, residues 155–
159, is unique to JCV tAg.
To determine whether JCV tAg interacts with the Rb family of
proteins, we performed co-IP/WB upon lysates from cells
expressing all five JCV early proteins or tAg alone, and with total
protein amounts adjusted to comparable levels of tAg expression in
each cell line. Lysates were incubated with Molt 4 extracts
overnight to compensate for the low levels of expression of Rb
proteins in the rat and mouse cells [7,8], immunoprecipitated with
anti- p107 antibody and immunoblotted with a cocktail of
antibodies that recognize the JCV early tumor proteins. All five
JCV early proteins bound p107. The interaction between T9165
and p107 is difficult to detect, not only because T9165 binding is
inefficient [7], but also because it is expressed at low levels relative
to the other early viral proteins. Wild type JCV tAg present in both
rat and mouse cells expressing the intact JCV early region was
found to interact comparably with p107 (Fig. 4, lanes 7–9), while
the binding of tAg to p107 without co-expression of the other four
early proteins was only slightly decreased (Fig. 4, lane 11). The
C157A tAg which carries a mutation that disrupts one LxCxE
domain, also interacted with p107 (Fig. 4, lane 10). Comparable
binding of the wild type and mutant tAgs to p130 was also
detected (data not shown). As noted with the other JCV early
Figure 2. Comparison of JCV and SV40 tAg amino acid sequences. The JCV tAg sequence containing 172 amino acids is indicated in red
letters, and the 174 amino acid SV40 tAg is shown in black letters. The sequences following the vertical line comprise the unique C-terminal region of
each protein. Two conserved cysteine (CxCxxC) clusters (Cluster 1, 2) that contribute to SV40 tAg binding to zinc ions, and possibly to PP2A, are noted
in both sequences, as are two recently recognized LxCxE motifs in JCV tAg. Three amino acid residues are highlighted with a blue letter and arrow.
Histidine 42 (H42) is a conserved residue in the HPDKGG hexapeptide motif of the J domain that spans most of the N-terminal region of tAg as well as
the other JCV and SV40 early proteins; H42 is required for functional interaction with Hsc70. Proline 99 is within a conserved CxxxPxC sequence that
influences SV40 tAg binding to PP2A. Cysteine 157 is the central residue of the newly recognized second LxCxE motif in JCV tAg.
doi:10.1371/journal.pone.0010606.g002
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detect, most likely because levels of this tumor suppressor protein
are low in these cells (data not shown; [7]).
JCV tAg Contributes to Viral DNA Replication in
Permissive Cells
SV40 TAg is recognized as the primary DNA replication
protein. It is the only viral protein required to initiate viral DNA
replication in a cell-free system [42], and in cultured cells, SV40
genomes encoding TAg without tAg are viable, although virus
titers may be reduced relative to parental SV40 [43]. JCV TAg is
also necessary and sufficient to promote viral DNA replication in a
cell-free system [44]. However, in vivo, the JCV T9 proteins
contribute to replication potential, and the contributions of tAg are
unknown [45]. To examine the individual roles of the JCV early
proteins in viral DNA replication, the intact wild-type JCV
genome (JR:T
+/t
+/T9
+), a TAg only mutant (JR:T
+/t
2/T9
2), a
TAg deletion mutant (JR:muT
+/t
+/T9
+), a tAg only mutant,
(JR:T
2/t
+/T9
2), a tAg null mutant (JR:T
+/t
2/T9
+), and a T9 only
mutant (JR:muT
+/t
2/T9
+) were each transfected into two plates
of PHFG cells (Fig. 5). Low-molecular DNA was extracted from
the cells at several times p.t., and DNA replication was measured
using a DpnI assay [46]. At day 0, equivalent amounts of input
DNA were detected for each sample; at all subsequent time points,
days 10, 14, and 21 p.t., increasing levels of the replicated wild
type JCV genome were detected. No replication of any DNA
construct lacking either TAg or tAg was observed in vivo at any
time point.
To further examine tAg’s role in viral DNA replication, the
Dpn1 assay was repeated with the same DNA constructs used in
Figure 5 plus the two tAg substitution mutants (JR:T
+/P99At
+/
T9
+ and JR:T+/C157At
+/T9
+) and a T9 null mutant (JR:T
+/t
+/
T9
2) (Fig. 6). At day 0, only input DNA was detected (data not
shown), but at later time points, increasing levels of Dpn1-resistant
replicated JCV DNA were observed with the two tAg point
mutants and the T9 deletion mutant; the other DNA constructs
exhibited the same replication behavior observed in the previous
experiment (Fig. 5). Genomes containing the P99A and C157A
tAg mutations exhibited reduced replication potential relative to
wild type JCV DNA (3–4% and 20–29%, respectively, depending
Figure 3. Interaction of mutant JCV tAgs with PP2A. Interactions between PP2A and wild-type tAg and (A) tAg-mutant P99A or (B) C157A were
compared. 3T3 cells were stably transfected with DNA constructs expressing JCV early proteins under the control of SV40 promoter-enhancer signals.
Lysates of these cells were subjected to IP with the anti-T monoclonal antibody PAb 962 (a-T) or anti-PP2A antibody (a-PP2A). The amount of total
cell protein subjected to IP with anti-PP2A antibody (lanes 5–8, Panel A; lanes 6–10, Panel B) was five times that used with the anti-T antibody (lanes
1–4, Panel A; lanes 1–5, Panel B). Samples were electrophoresed on 18% SDS-polyacrylamide gels and transferred to nitrocellulose membranes. WB
was performed using a cocktail of anti-T monoclonal antibodies. Results for two independently-derived cells lines (#1, #2) containing DNA
constructs that either encode all 5 JCV wild type early proteins (T
+/t
+/T9
+; Panel A, lanes 1,2,5,6, Panel B, lanes 1,2,6,7) or wild type TAg, T9165,T 9136 and
T9135 plus tAg mutant P99A (T
+/P99At
+/T9
+; Panel A, lanes 3,4,7,8) or C157A (T
+/C157At
+/T9
+; Panel B, lanes 3,4,8,9) are shown. A single 3T3 cell line
expressing tAg only (T
2/t
+/T9
2) was isolated and tested for PP2A binding (Panel B, lanes 5, 10). Panels A and B of this figure each represent proteins
electrophoresed on a single gel and transferred to a membrane, which was then cut in half and each half developed for different lengths of time.
doi:10.1371/journal.pone.0010606.g003
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+/t
+/T9
2 DNA
replication was reduced more than 10-fold (6–8% of wild type).
DNA replication of the tAg null mutant was not detected at any
time point, confirming the results presented in Figure 5 indicating
that JCV tAg has a significant influence upon this critical activity.
Expression of JCV tAg in trans does not Relieve the
Replication Defect of JR:T
+/t
2/T9
+
An SV40 H42Q mutant altered at a critical residue of the
shared J domain of the three early proteins is replication-defective
[16]. We created an H42Q mutant of JCV tAg to see if this
alteration impacted tAg’s ability to support DNA replication.
Because the mutation affected the other four JCV early proteins as
well, we introduced the H42Q mutation into a construct that only
expresses tAg to generate JR:T
2/H42Qt
+/T9
2. This DNA, or a
DNA expressing wild type tAg only, was co-transfected into cells
with a construct expressing wild type TAg and the three T9
proteins, but not tAg (JR:T
+/t
2/T9
+), to determine if tAg
expression complemented replication of the latter DNA in trans.
Dpn1-resistent DNA was not detected using either combination of
co-transfected DNAs at any time point, although replication was
observed with the wild type control construct (JR:T
+/t
+/T9
+) and
to a lesser extent with the construct lacking the T9 proteins
(JR:T
+/t
+/T9
2) (Fig. 7). The absence of detectable complemen-
tation with the wild type tAg precludes a determination of whether
the H42Q mutation in tAg impacts this protein’s replication
function.
Elevated Expression of JCV TAg and T9 Proteins Promotes
DNA Replication in the Absence of tAg
The levels of viral proteins expressed from the JCV transcrip-
tional signals are low relative to the levels induced by the SV40
signals [35,47]. We hypothesized that if JCV early protein
expression was increased, viral DNA replication might be elevated
to detectable levels for some replication-defective JCV constructs,
including the tAg deletion mutant. Although the SR:T
+/t
2/T9
+
Figure 4. Wild type and mutant JCV tAgs bind the Rb protein p107. JCV early proteins expressed in Rat 2 (R2) or MEF cells transformed with
pSR:T
+/t
+/T’
+ (encodes all 5 JCV early proteins) or in G418-selected 3T3 cells stably transfected with pSR:T
+/t
+/T’
+, pSR:T
2/t
+/T’
2 (encodes tAg only) or
pSR:T
+/C157At
+/T’
+ (encodes tAg mutated at residue 157 and the other 4 JCV early proteins) were incubated with anti-T monoclonal antibody PAb
962 (a-T; lanes 2–6) or anti-p107 antibody (a-p107; lanes 7–11). Negative controls included EBC lysis buffer immunoprecipitated with anti-T
monoclonal antibody PAb 962 (Con, lane 1) and Molt 4 extract with anti-p107 antibody (Molt 4, lane 12). The amount of total cell protein subjected to
IP in lanes 7–11 was 10 times that employed in the corresponding samples in lanes 2–6. Proteins were separated on an 18% SDS-polyacrylamide gel
and WB analysis was performed using a cocktail of anti-T monoclonal antibodies. The asterisks denote antibody light and heavy chains. This figure
represents proteins electrophoresed on a single gel and transferred to a membrane, which was then cut in half and each half developed for different
lengths of time.
doi:10.1371/journal.pone.0010606.g004
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prediction, the JCV early proteins in this chimeric DNA do not
productively interact with the SV40 origin sequences to mediate
viral DNA replication [38]. To overcome this obstacle, PHFG cells
were co-transfected with two DNAs, the first was a construct
containing the JCV origin of replication (pM1o; [38]) and the
second was one of three constructs containing wild type (T
+/t
+/
T9
+) or mutant (T
+/t
2/T9
+ or T
+/t
2/T9
2) JCV early coding
regions under the control of a CMV promoter. This DpnI assay
differed from those described above in at least three ways: (i) the
CMV promoter is more active than the JCV transcriptional signals
and the T proteins are expressed at higher levels, (ii) the constructs
contain the JCV early coding region linked to plasmid sequences
rather than the intact JCV genome and (iii) the JCV proteins and
replication origin are not resident on the same DNA molecule.
Following co-transfection of PHFG cells, replicated viral DNA was
isolated at days 0, 3, 4, and 5 p.t. Replication of the origin plasmid
pM1o was detected at days 3, 4 and 5 p.t. in the presence of
pCMV:T
+/t
+/T9
+ (Fig. 8). At days 4 and 5 p.t., the small t null
construct, pCMV:T
+/t
2/T9
+, mediated replication of the pM1o
vector at less than 10% the level observed in the presence of all 5
JCV early proteins. No replication was detected at any time point
in the presence of the construct expressing TAg only (pCMV:T
+/
t
2/T9
2), suggesting that at least some contributions of the tAg and
the T9 proteins to DNA replication are unique.
Discussion
A substantial number of biological differences have been
documented between the primate polyomaviruses JCV and
SV40, yet the sequence and the organization of the two viral
genomes are remarkably similar[ 2 ] .E a r l ys t u d i e se m p l o y i n g
chimeric viruses indicated the transcriptional control regions of
each virus, including their viral promoter and enhancer
elements, have a significant impact on the individual trans-
forming and lytic behaviors of JCV vs. SV40 [35,38,48,49].
Figure 5. Replication efficiencies of DNA constructs expressing combinations of JCV early proteins. PHFG cells in 60 mm plates were
transfected in duplicate with 400 ng of wild type (T
+/t
+/T’
+) or mutant (T
+/t
2/T’
2, muT
+/t
+/T’
+,T
2/t
+/T’
2,T
+/t
2/T’
+, or muT
+/t
2/T’
+) JCV genomes. At
each time point, viral DNA was extracted by the Hirt procedure [39], purified, digested with DpnI and EcoRI, electrophoresed on a 0.8% agarose gel,
transferred to nitrocellulose membranes and hybridized to a [P
32]dCTP-labeled JCV DNA probe. Bands were visualized with a Typhoon
phosphorimager and quantitated with ImageQuant software. The marker (M) shown in the first lane of each blot is 1 ng of linear JCV DNA (5130 bp).
The duplicate, independent samples representing each DNA construct were analyzed, and the position of Dpn1-resistent replicating genomes on the
Southern blots is denoted by an arrow at days 10, 14 and 21 p.t. Dpn1- and EcoRI-sensitive input DNAs are noted at the day 0 time point. Hirt extracts
of uninfected PHFG cells (PHFG) were subjected to the same Dpn1 assay.
doi:10.1371/journal.pone.0010606.g005
JCV Small t Protein Functions
PLoS ONE | www.plosone.org 8 May 2010 | Volume 5 | Issue 5 | e10606These sequences have diverged to the greatest extent with only
44% sequence identity between JCV and SV40. Experiments
with the hybrid viral genomes also revealed the early coding
regions to be sources of biological variation [35,48,50].
Although the N-terminal region of the tAgs share 82% sequence
identity, the unique C-terminal portions, with only 54%
identity, represent the sequences with the least amount of
similarity among the early proteins; these sequences were the
primary focus of the current study.
Very little work has been conducted with the JCV tAg, although
numerous studies with its SV40 counterpart suggest interesting
initial experiments to perform. The binding of the unique region
of the SV40 tAg to PP2A provides the mechanism by which tAg
induces most observed alterations to the behavior and morphology
of cells [22,31,51–54]. The only other interaction predicted for
SV40 tAg occurs with the molecular chaperone Hsc70 via its J
domain located within the N-terminal 82 amino acid sequences
shared with TAg and 17kT. JCV tAg may bind to these and
additional cellular and viral proteins. Purified GST-JCV tAg
prepared in bacteria binds PP2A in vitro [40], and JCV tAg
expressed in mammalian cells binds PP2A in vivo (current study).
Many of the outcomes reported to result from the SV40 tAg-PP2A
interaction, including those involving the activation of the PI3K
and MAPK pathways, are likely to occur following contact
between JCV tAg and PP2A. The JCV tAg has been shown to
interfere with the phosphatase activity of PP2A in studies involving
a second known binding partner of tAg, the JCV agnoprotein [40].
We were surprised to identify two LxCxE motifs that had been
overlooked in the unique region of the JCV tAg; one of these sites
is also found in BKV but neither site resides in the corresponding
SV40, WUV, KIV or MCV polyomavirus proteins. As predicted,
JCV tAg binds members of the retinoblastoma protein family.
These interactions are relevant to the potential contributions tAg
may make to JCV oncogenic activities. While the tAg-PP2A
interaction may activate signaling pathways critical to cell growth
and survival, effects on Rb proteins may also influence these
processes via cell cycle regulation. The LxCxE motif and the
tripeptide HDP of the J domain of the polyomavirus tumor
proteins make direct contacts with the Rb proteins and Hsc70,
respectively; together they effect the release of members of the E2F
family of transcription factors from their Rb partners to promote
cell cycle progression [reviewed in 55].
There is less certainty about the identity of tAg amino acids that
are in direct contact with PP2A. Mutations introduced into the
two CxCxxC clusters in the C terminus of SV40 tAg yield an
unstable protein and disrupt zinc binding [23]. Under these
conditions, the role of these two clusters in PP2A binding could not
be determined. Mutations to the two cysteines and one proline of
the CxxxPxC motif located upstream of the CxCxxC clusters did
reduce PP2A binding significantly. Additional studies that relied
upon peptide inhibition of the tAg-PP2A interaction without
destabilizing tAg suggested that the CxCxxC clusters might indeed
influence tAg binding to the A subunit [23,25]. Two recent X-ray
crystallographic studies indicate the CxCxxC clusters and the
CxxxPxC sequence in the C terminus of SV40 tAg and the
HDPKGG sequence of the N-terminal J domain contribute to tAg
binding to the scaffolding A and catalytic C subunits of PP2A
[53,54].
To begin to identify JCV tAg residues critical to PP2A and Rb
interactions and to DNA replication activity, we introduced
mutations into the conserved CxxxPxC sequence and the unique
LxCxE motif within the C-terminus of JCV tAg. Using a co-
immunoprecipitation approach, we confirmed our prediction that
the P99A mutant tAg would exhibit a loss of PP2A binding
activity. This proline is conserved in the tAgs of primate
polyomaviruses as well as of mouse polyoma virus.
Figure 6. Mutation of tAg residues proline 99 and cysteine 157 reduce JCV DNA replication. PHFG cells in 60 mm plates were transfected
in duplicate with 400 ng of wild type (T
+/t
+/T’
+) or 8 different mutant (muT
+/t
2/T’
+,T
+/P99At
+/T’
+,T
+/C157At
+/T’
+,T
+/t
+/T’
2,T
+/t
2/T’
2, muT
+/t
+/T’
+,
T
2/t
+/T’
2,T
+/t
2/T’
+) JCV genomes. Duplicate, independent samples representing each DNA construct were extracted by the method of Hirt [39] on
days 0, 7, 10 and 14 p.t. and analyzed using the Dpn1 assay as described in the legend to Figure 5. The marker (M) shown in the first lane of each blot
is 1 ng of linear JCV DNA (5130 bp), and the position of Dpn1-resistent replicating genomes is denoted by an arrow at days 7, 10 and 14 p.t.
doi:10.1371/journal.pone.0010606.g006
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conserved cysteine in the newly recognized LxCxE domain of
JCV tAg was required for Rb binding. However, once made, we
also tested whether the mutant displayed altered PP2A binding
relative to wild type tAg. In one cell line, we found that the C157A
tAg bound PP2A with wild type efficiency. We consistently
observed; however, that the same mutant tAg expressed in a
second, independently derived cell line bound PP2A even better
than wild type tAg. A preliminary comparison of the two cell lines
expressing the C157A tAg indicates that the line in which more
efficient PP2A binding occurred had a shorter doubling time and
more transformed morphology. This observation will require
additional investigation to determine if enhanced PP2A binding is
associated with a transformed phenotype.
It should be noted that to detect PP2A binding in this study, we
employed antibodies that recognized the catalytic subunit of
PP2A. PP2A is found abundantly as either a holoenzyme
consisting of the AC core plus a regulatory B subunit, or as the
AC core alone. High levels of the A and C subunits are not found
as free proteins in cells [56], and SV40 tAg does not bind
detectably to purified free C subunit [57]. Given this information,
our data suggest JCV tAg binds the scaffold subunit (A) of the AC
core of PP2A in rat and mouse fibroblasts and not directly to the C
subunit.
As noted above, the C157A tAg mutant was created to see if
alteration of the second LxCxE motif would affect Rb binding. In
addition, the CxxxPxC motif containing the P99A mutation
overlaps the first LxCxE domain in the JCV protein. Neither
mutation had a detectable affect on the ability of tAg to bind p107
(Fig. 4) or p130 (data not shown). It is likely that both LxCxE
motifs contribute to Rb binding, perhaps redundantly, and that to
abolish binding activity, double mutants will have to be created
Figure 8. JCV early genes expressed from a CMV promoter
induce replication of a JCV origin plasmid. PHFG cells in 60 mm
plates were co-transfected in duplicate with 400 ng of the JCV
replication origin plasmid, pM1o, and 400 ng of one of the following
expression vectors that encode JCV early genes under the control of the
CMV promoter: pCMV:T
+/t
+/T9
+ (lanes 2, 3; all five tumor proteins
expressed), pCMV:T
+/t
2/T9
+ (lanes 4, 5; TAg and 3 T9 proteins expressed)
or pCMV:T
+/t
2/T9
2 (lanes 6, 7; TAg only expressed). The ability of the
proteins produced by the second plasmid to drive replication of the
origin plasmid in trans was tested. Duplicate, independent samples
representing each DNA construct were extracted by the method of Hirt
[39] on days 0, 3, 4 and 5 p.t. and analyzed using the Dpn1 assay as
described in the legend to Figure 5. The marker (M) shown in lane 1 of
each blot is 1 ng of linear pM1o (,2400 bp), and the position of Dpn1-
resistent replicating genomes is denoted by an arrow at days 3–5 p.t.
Dpn1- and EcoRI-sensitive input DNAs are noted at the day 0 time point.
doi:10.1371/journal.pone.0010606.g008
Figure 7. JCV tAg fails to complement replication of a tAg-
deficient JCV genome in trans. PHFG cells in 60 mm plates were co-
transfected in duplicate with 400 ng of a tAg-deficient (T
+/t
2/T’
+) JCV
genome and 400 ng of a JCV DNA construct expressing either wild type
tAg (T
2/t
+/T9
2) or a J domain mutant tAg (T
2/H42Qt
+/T9
2) under the
control of the JCV promoter-enhancer. Cells were also transfected with
400 ng of either a T9-deficient (T
+/t
+/T’
2) JCV genome or a positive
replication control (T
+/t
+/T’
+). Duplicate, independent samples repre-
senting each DNA construct were extracted by the method of Hirt [39]
on days 0, 7, and 10 p.t. and analyzed using the Dpn1 assay as
described in the legend to Figure 5. The marker shown in the first lane
of each blot is 1 ng of linear JCV DNA (5130 bp), and the position of
Dpn1-resistent replicating genomes is denoted by an arrow at days 7
and 10 p.t. Dpn1- and EcoRI-sensitive input DNAs are noted at the day 0
time point.
doi:10.1371/journal.pone.0010606.g007
JCV Small t Protein Functions
PLoS ONE | www.plosone.org 10 May 2010 | Volume 5 | Issue 5 | e10606and tested. It is also possible that neither LxCxE motif is required
for Rb binding, as a number of cellular proteins lacking this
sequence do functionally interact with pRB, p107 and p130 [58].
Furthermore, sequences in addition to the LxCxE motif contribute
to the ability of some viral oncoproteins to bind Rb proteins
[59,60].
SV40 TAg has long been recognized at the key replication
protein of this virus, and in vivo and in vitro studies have confirmed
this role for JCV TAg as well. Regulation of SV40 DNA
replication involves the incompletely understood coordination of
TAg phosphorylation and dephosphorylation. Phosphorylation of
serines 120 and 123 negatively regulates TAg functions, whereas
phosphorylation of threonine 124 is required for TAg-mediated
replication [reviewed in 20,21]. Modifications to the correspond-
ing residues in JCV TAg, serines 121 and 124 and threonine 125,
have been proposed, and threonine 125 has been demonstrated to
be essential to replication activity [61,62]. A cell-free DNA
replication system utilizing SV40 TAg indicated that addition of
PP2A enhances DNA replication and that SV40 tAg inhibits this
effect by blocking dephosphorylation of serines 120 and 123
[63,64]. However, SV40 tAg appears to stimulate SV40
replication to a limited extent in vivo; SV40 tAg deletion mutants
produce slightly lower numbers of virions per infected cell [43] and
addition of tAg protein to cells infected with SV40 tAg-defective
genomes stimulates DNA replication [20]. Recently, tAg was
shown to have a significant effect on DNA replication of the
human polyomavirus MCV [65]. In the absence of tAg, TAg-
mediated replication is reduced nearly 10-fold in 293 cells. Nesper
et al. [44] developed a cell-free replication system to demonstrate
that TAg is the only JCV protein required to mediate in vitro
replication of a plasmid containing the JCV origin of replication.
Using an in vivo approach with permissive PHFG cells, it was
shown that JCV TAg is required for DNA replication, and JCV T9
proteins contribute to replication efficiency [45]. Further, a
truncated JCV tAg mutant, encoding amino acids 1–89, replicated
with similar efficiency to wild type JCV at days 7 and 14 p.t., but
significant inhibition was observed at a later time point [40]. The
authors speculated that reduced replication resulted from the
inability of the mutant tAg to inhibit PP2A, thereby leading to
dephosphorylation of the late JCV agnoprotein and inefficient
DNA replication. In the current study we found that a JCV
genome missing only tAg failed to replicate to detectable levels in
PHFG cells. By modifying the replication assay and increasing
expression of the JCV early proteins under the control of more
potent CMV transcriptional signals, low levels of JCV DNA
replication (,10% of wild type; Fig. 8) were observed; a construct
lacking tAg and the three T9 proteins, however, still failed to
replicate under these conditions. The inability of the CMV:T
+/
t
2/T9
2 construct to drive replication of the JCV origin plasmid
suggests that not all contributions of the tAg and the T9 proteins to
DNA replication are redundant. These data indicate that JCV
tAg, unlike its SV40 counterpart but similar to MCV tAg, makes a
significant contribution to viral DNA replication activity, and
furthermore, that its effect on agnoprotein phosphorylation status
does not completely explain its role in replication, since
agnoprotein was not present in our assay. We speculate that
interactions of tAg with PP2A and Rb proteins alter JCV TAg
phosphorylation status and promote cell cycle progression, leading
to conditions more favorable to viral DNA replication.
We also tested whether the H42Q, P99A and C157A mutations
in JCV tAg had any effect on viral DNA replication. Because the
latter two mutations reside in the unique coding sequences of tAg,
this protein could be altered without affecting the other four early
proteins. However, the H42Q mutation affects the shared N
terminus of all five early proteins. To determine if the H42Q
mutation affected DNA replication behavior, we co-transfected the
JR:T
+/t
2/T9
+ genome into PHFG cells with either the wild type
or H42Q mutant tAg construct. We predicted this approach
would allow us to determine whether H42Q tAg complemented
the tAg-defective genome (i.e. JR:T
+/t
2/T9
+). While no replica-
tion was observed in this case, the control which employed the
wild type tAg also failed to complement the tAg-defective DNA,
and no conclusion could be reached regarding the influence of this
J domain residue upon JCV DNA replication. This experiment
does; however, provide new information indicating that expression
of tAg in trans fails to correct the replication defect of a tAg-
deficient JCV genome. It is possible that the levels of tAg produced
from the JCV transcriptional signals are insufficient to permit
detection of a complementing activity. It should be noted that a
similar mutation to the J domain of the MCV tAg did not alter
DNA replication behavior, while the same mutation in the MCV
TAg markedly reduced this activity [65].
We demonstrated that the P99A mutant, and to a lesser extent
the C157A mutant, exhibits a significant reduction in DNA
replication relative to that observed with wild-type JCV. Thus,
proline 99 and cysteine 157 are likely to either affect tAg’s ability to
cooperate with the other T proteins or with cellular proteins that
influence DNA replication potential and/or cell proliferation and
survival. We have shown that the P99A mutation alters one such
interaction, i.e. binding to PP2A. Significantly, Kwun and co-
workers [65] reported that a mutation to a CxCxxC motif in the
MCV tAg, abrogated the ability of this protein to stimulate DNA
replication. The authors suggested that loss of binding to PP2A by
the MCV mutant tAg affected the phosphatase’s ability to modify
cellular or viral targets that impact replication either directly or
indirectly.
JCV tAg possesses unique features among polyomavirus small t
proteins. Unlike SV40 tAg, it plays a significant role in the
replication of viral DNA in vivo. SV40 tAg has been found to
interact with PP2A, and it is predicted to bind Hsc70. In addition
to these two cellular proteins, JCV tAg binds to the viral
agnoprotein and to the Rb proteins, pRB, p107 and p130, most
likely via two unique LxCxE motifs. Cooperation between the
LxCxE and J domains of JCV tAg are expected to influence cell
cycle progression. The study of JCV tAg has only recently been
pursued, and it is expected that a greater understanding of this
viral tumor protein will provide new insights into the pathogenic
and oncogenic potentials of this human virus.
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